Phase II trial of dexverapamil and epirubicin in patients with non-responsive metastatic breast cancer
1998

Dexverapamil and Epirubicin in Metastatic Breast Cancer

Sample size: 39 publication Evidence: moderate

Author Information

Author(s): M Lehnert, K Mross, J Schueller, B Thuerlimann, N Kroeger, H Kupper

Primary Institution: Kantonsspital St Gallen

Hypothesis

Can dexverapamil enhance the effectiveness of epirubicin in patients with non-responsive metastatic breast cancer?

Conclusion

The addition of dexverapamil to epirubicin resulted in partial responses in some patients without increasing toxicity.

Supporting Evidence

  • Dexverapamil did not increase epirubicin toxicity.
  • The area under the plasma concentration-time curve of epirubicin was significantly reduced by dexverapamil.
  • Partial responses were observed in 4 out of 23 patients evaluable for tumor response.
  • The mean trough plasma levels of dexverapamil and its major metabolite were 1.2 and 1.5 µM respectively.

Takeaway

Doctors tested a new drug called dexverapamil to see if it could help another drug, epirubicin, work better for women with tough breast cancer. Some women got better when they took both drugs together.

Methodology

Patients received epirubicin alone, and those with refractory disease were given dexverapamil alongside epirubicin.

Potential Biases

Potential bias due to the lack of randomization and the small number of patients evaluated for response.

Limitations

The study had a small sample size and lacked a control group.

Participant Demographics

Thirty-nine women aged 18-65 with metastatic breast cancer.

Statistical Information

P-Value

0.02

Confidence Interval

5-39%

Statistical Significance

p=0.02

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication